Research programme: opioid therapeutics - Elite Pharmaceuticals

Drug Profile

Research programme: opioid therapeutics - Elite Pharmaceuticals

Alternative Names: ELI-400; ELI-500; ELI-501; ELI-600; ELI-601; Opioid products - Elite Pharmaceuticals

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elite Pharmaceuticals
  • Class Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Pain

Most Recent Events

  • 09 Aug 2017 Elite Pharmaceuticals has patent protection relating to opioid abuse deterrent technology in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top